FDA Approves Libtayo for NSCLC With High PD-L1 Expression
Libtayo is now approved for the first-line treatment of patients. Call our team at 972-548-9690 to see if this treatment is right for you.
FDA Approves Libtayo for NSCLC With High PD-L1 Expression
TAGRISSO- New Indications for Non Small Cell Lung Cancer!
Acute promyelocytic leukemia (APL) in a patient with Crohn's disease and exposure to infliximab: a
Composite Diffuse Large B-cell and Mantle Cell Lymphoma: A Case Report
Patients' Experience with Dr. Khan
Testosterone Levels and Quality of Life in Diverse Male Patients With Cancers Unrelated to Androgens
New drug approval by FDA for MDS related anemia
Our Response to COVID-19